NO20055688L - Organiske forbindelser - Google Patents

Organiske forbindelser

Info

Publication number
NO20055688L
NO20055688L NO20055688A NO20055688A NO20055688L NO 20055688 L NO20055688 L NO 20055688L NO 20055688 A NO20055688 A NO 20055688A NO 20055688 A NO20055688 A NO 20055688A NO 20055688 L NO20055688 L NO 20055688L
Authority
NO
Norway
Prior art keywords
compounds
organic compounds
muscarinic
meanings
receptor
Prior art date
Application number
NO20055688A
Other languages
English (en)
Norwegian (no)
Other versions
NO20055688D0 (no
Inventor
Gurdip Bhalay
Stephen Paul Collingwood
Brian Cox
Urs Baettig
Nicholas James Devereux
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33420896&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20055688(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0324887A external-priority patent/GB0324887D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20055688D0 publication Critical patent/NO20055688D0/no
Publication of NO20055688L publication Critical patent/NO20055688L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20055688A 2003-05-02 2005-12-01 Organiske forbindelser NO20055688L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0310232 2003-05-02
GB0324887A GB0324887D0 (en) 2003-10-24 2003-10-24 Organic compounds
PCT/EP2004/004605 WO2004096800A2 (en) 2003-05-02 2004-04-30 Quinuclidine derivatives binding to mucarinic m3 receptors

Publications (2)

Publication Number Publication Date
NO20055688D0 NO20055688D0 (no) 2005-12-01
NO20055688L true NO20055688L (no) 2006-01-09

Family

ID=33420896

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055688A NO20055688L (no) 2003-05-02 2005-12-01 Organiske forbindelser

Country Status (32)

Country Link
US (2) US20070060563A1 (da)
EP (1) EP1631569B1 (da)
JP (1) JP4416786B2 (da)
KR (1) KR100896544B1 (da)
AR (1) AR044134A1 (da)
AT (1) ATE440840T1 (da)
AU (1) AU2004234069B2 (da)
BR (1) BRPI0410238A (da)
CA (1) CA2523436C (da)
CL (1) CL2004000918A1 (da)
CO (1) CO5700782A2 (da)
CY (1) CY1109655T1 (da)
DE (1) DE602004022805D1 (da)
DK (1) DK1631569T3 (da)
EC (1) ECSP056134A (da)
ES (1) ES2331185T3 (da)
HK (1) HK1087704A1 (da)
HR (1) HRP20050933A2 (da)
IL (1) IL171591A (da)
IS (1) IS2746B (da)
MA (1) MA27775A1 (da)
MX (1) MXPA05011739A (da)
MY (1) MY142652A (da)
NO (1) NO20055688L (da)
NZ (1) NZ542995A (da)
PE (1) PE20050465A1 (da)
PL (1) PL1631569T3 (da)
PT (1) PT1631569E (da)
RU (1) RU2363700C2 (da)
SI (1) SI1631569T1 (da)
TW (1) TWI340139B (da)
WO (1) WO2004096800A2 (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2239546B1 (es) * 2004-03-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos esteres de quinuclidina cuaternizados.
GB0410712D0 (en) 2004-05-13 2004-06-16 Novartis Ag Organic compounds
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0428416D0 (en) * 2004-12-24 2005-02-02 Novartis Ag Organic compounds
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
EP1894568A1 (en) * 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
EP1900737A1 (en) * 2006-08-31 2008-03-19 Novartis AG Polymorph of (R)-3-(2-hydroxy-2,2-diphenyl-acetoxy)-1-(isoxazol-3-ylcarbamoyl-methyl)-1-azonia-bicyclo-[2.2.2]octane bromide
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
ES2385681T3 (es) * 2006-12-19 2012-07-30 Astrazeneca Ab Derivados de quinuclidinol como antagonistas de receptores muscarínicos
EP1950196A1 (de) * 2007-01-29 2008-07-30 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Herstellung von Ammoniumhexafluorophosphaten
MX2010002576A (es) 2007-09-07 2010-04-01 Theravance Inc Compuestos que contienen guanidina, utiles como antagonistas de los receptores muscarinicos.
WO2009079392A1 (en) 2007-12-14 2009-06-25 Theravance, Inc. Amidine-containing compounds useful as muscarinic receptor antagonists
KR20100113557A (ko) 2008-01-11 2010-10-21 노파르티스 아게 키나제 억제제로서의 피리미딘
BRPI0912657A2 (pt) * 2008-05-13 2016-01-26 Astrazeneca Ab produto farmacêutico compreendendo um antagonista de receptor muscarínico e um agonista beta2-adrenorreceptor
GB0808709D0 (en) * 2008-05-13 2008-06-18 Astrazeneca Ab New combination 295
BRPI0822693A2 (pt) * 2008-05-13 2015-07-07 Astrazeneca Ab Derivados de quinuclidina como antagonistas do receptor muscarínico m3
US20090326004A1 (en) 2008-06-03 2009-12-31 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
WO2009153536A1 (en) * 2008-06-17 2009-12-23 Argenta Discovery Limited 1-aza-bicyclo [2.2.2] octane derivatives useful as muscarinic receptor antagonists
GB0811100D0 (en) * 2008-06-17 2008-07-23 Astrazeneca Ab New combination
CA2803459A1 (en) * 2010-06-22 2011-12-29 Chiesi Farmaceutici S.P.A. Alkaloid aminoester derivatives and medicinal compositions thereof
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
US9102671B2 (en) 2011-02-25 2015-08-11 Novartis Ag Compounds and compositions as TRK inhibitors
JP2011195593A (ja) * 2011-06-30 2011-10-06 Astrazeneca Ab ムスカリンｍ３受容体アンタゴニストとしてのキヌクリジン誘導体
CN104011043B (zh) * 2011-12-30 2016-11-16 奇斯药制品公司 作为抗毒蕈碱剂的1-氮杂杂环基乙酸的奎宁环酯、它们的制备方法及其药用组合物
WO2013166413A2 (en) * 2012-05-03 2013-11-07 Saint Louis College Of Pharmacy Compositions and methods for increasing neurotrophic peptides
TWI647227B (zh) * 2013-02-28 2019-01-11 日商安斯泰來製藥股份有限公司 ２－醯胺噻唑衍生物或其鹽
CZ306791B6 (cs) 2013-10-29 2017-07-12 Zentiva, K.S. Průmyslově využitelný způsob přípravy aklidinium bromidu o vysoké čistotě
PT108370B (pt) * 2015-03-30 2018-10-25 Hovione Farm S A Processo de preparação de brometo de aclidínio
PT3111978T (pt) 2015-07-03 2021-12-06 Novartis Ag Inalador adaptado para ler informação armazenada num meio de armazenamento de dados de um recipiente

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1219606A (en) * 1968-07-15 1971-01-20 Rech S Et D Applic Scient Soge Quinuclidinol derivatives and preparation thereof
DK534178A (da) * 1977-12-16 1979-06-17 Interx Research Corp Anticholinerge midler med sektrtionshaemmende virkning
ES2165768B1 (es) * 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
WO2002004402A1 (fr) * 2000-07-11 2002-01-17 Banyu Pharmaceutical Co., Ltd. Derives d'ester
SK287414B6 (sk) * 2000-12-28 2010-09-07 Laboratorios Almirall, S.A. Chinuklidínové deriváty a kompozície s ich obsahom
MXPA04006206A (es) * 2001-12-20 2004-12-06 S A L V A T Lab Sa Derivados de 1-alquil-azoniabiciclo(2.2.2(octano carbamato y su uso como antagonistas del receptor musrcarinico.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
EP1900737A1 (en) * 2006-08-31 2008-03-19 Novartis AG Polymorph of (R)-3-(2-hydroxy-2,2-diphenyl-acetoxy)-1-(isoxazol-3-ylcarbamoyl-methyl)-1-azonia-bicyclo-[2.2.2]octane bromide

Also Published As

Publication number Publication date
ES2331185T3 (es) 2009-12-23
RU2005137360A (ru) 2006-07-27
CO5700782A2 (es) 2006-11-30
RU2363700C2 (ru) 2009-08-10
CA2523436C (en) 2011-11-01
ECSP056134A (es) 2006-04-19
US8168654B2 (en) 2012-05-01
DE602004022805D1 (de) 2009-10-08
EP1631569B1 (en) 2009-08-26
JP2006525267A (ja) 2006-11-09
AU2004234069A1 (en) 2004-11-11
NZ542995A (en) 2009-02-28
WO2004096800A2 (en) 2004-11-11
SI1631569T1 (sl) 2010-01-29
PT1631569E (pt) 2009-11-26
PE20050465A1 (es) 2005-07-18
IS8158A (is) 2005-11-30
HK1087704A1 (en) 2006-10-20
KR20060015572A (ko) 2006-02-17
NO20055688D0 (no) 2005-12-01
AU2004234069B2 (en) 2008-02-21
CL2004000918A1 (es) 2005-02-11
PL1631569T3 (pl) 2010-02-26
JP4416786B2 (ja) 2010-02-17
KR100896544B1 (ko) 2009-05-07
WO2004096800A3 (en) 2005-01-06
DK1631569T3 (da) 2009-11-23
IS2746B (is) 2011-08-15
HRP20050933A2 (en) 2006-12-31
MA27775A1 (fr) 2006-02-01
TW200505920A (en) 2005-02-16
CA2523436A1 (en) 2004-11-11
CY1109655T1 (el) 2014-08-13
BRPI0410238A (pt) 2006-05-16
MY142652A (en) 2010-12-15
EP1631569A2 (en) 2006-03-08
ATE440840T1 (de) 2009-09-15
IL171591A (en) 2010-11-30
TWI340139B (en) 2011-04-11
MXPA05011739A (es) 2006-01-26
US20100041887A1 (en) 2010-02-18
AR044134A1 (es) 2005-08-24
US20070060563A1 (en) 2007-03-15

Similar Documents

Publication Publication Date Title
NO20055688L (no) Organiske forbindelser
BRPI0519292A2 (pt) compostos orgÂnicos
NO20061406L (no) Organiske forbindelser
TW200519106A (en) Organic compounds
NO20074093L (no) Fremgangsmater for fremstilling av glukopyranosyl-substituerte benzyl-benzenderivater og mellomprodukter derav
TW200628154A (en) Organic compounds
ES2368594T3 (es) Derivados sustituidos de ciclohexilmetilo.
NO20060324L (no) [1,8]Naftyridin-2-oner og relaterte forbindelser for behandling av Schizofreni
NO20061363L (no) Pyrazolo- og imidazo- pyrimidinderivater
ATE541839T1 (de) Pyrrolidiniumderivate als m3-muskarinische rezeptoren
NO20074592L (no) Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister
NO20076197L (no) Nye 2-azetidinonderivater anvendbare i behandling av hyperlipidemiske tilstander
GB0305152D0 (en) Organic compounds
NO20076254L (no) Nye 2-azetidinonderivater som kolesterolabsorpsjonsinhibitorer for behandling av hyperlipidemiske tilstander
NO20076195L (no) Nye 2-azetidinonderivater for behandling av hyperlipidemiske sykdommer
NO20081217L (no) Nye benzotiazolonderivater
NO20076138L (no) Nye 2-azetidinonderivater som kolesterolabsorpsjonsinhibitorer for behandling av hyperlipidemiske tilstander
NO20092689L (no) Quinuclidinolderivater som muskarin reseptorantagonister
NO20074258L (no) Pyridin-2-karboksamidderivater som MGLUR5 antagonister
NO20076196L (no) Nye 2-azetidinonderivater som kolesterolabsorpsjonsinhibitorer for behandling av hyperlipidemiske tilstander
NO20091626L (no) MGLUR5-modulatorer
SE0401762D0 (sv) Novel compounds
NO20064351L (no) Caspaseinhibitorer og anvendelser derav
MXPA05013823A (es) Derivados de pirrolidinio y piperidino como ligandos para el receptor m3 muscarinico.
NO20060718L (no) Substituerte tiofoner og deres anvendelse

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application